BackChongqing Zhifei Biological Products , Ltd. Overview

Chongqing Zhifei Biological Products , Ltd. EBIT

Chongqing Zhifei Biological Products , Ltd.'s EBIT is $-17B, below the Healthcare sector average of $1.1T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$176.58M
↑ 127.79% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$16.61B
↓ 1000.14% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Chongqing Zhifei Biological Products , Ltd. (300122.SZ) FAQ

The latest EBIT for 300122.SZ is $-17B as of September 2026. That compares with $-1.5B in the prior-year period — down 1000.1% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside Chongqing Zhifei Biological Products , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 300122.SZ's EBIT moved from $-1.5B to $-17B — a 1000.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chongqing Zhifei Biological Products , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 300122.SZ currently prints $-17B for EBIT, while the sector average sits near $1.1T. That is roughly 101.5% below the sector mean. Large gaps often invite a closer look at Chongqing Zhifei Biological Products , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-17B for 300122.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.

After noting 300122.SZ's EBIT ($-17B), review year-over-year change from $-1.5B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers